Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897657 · ClinicalTrials.gov registry record
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
A clinical trial of Multiple Sclerosis (Relapsing Remitting), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 155
- Enrollment target
- 1
- Study location
NCT06897657 is a study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 155 participants, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06897657, a study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data. UK MS centers with National Health Service (NHS) databases and/or homecare and pharmacy services prescribing ofatumumab were identified and recruited for study participation using a feasibility assessment exercise. The study index identification window spanned from 26 March 2021 to 30 June 2023 (or latest data available prior to start of study data extraction). The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. From index date, patients were followed up until death, up to 13 months after index date, loss to follow-up, or end of study index identification window (whichever came first). For patients who consented to the use of their data, participating sites transcribed protocol required patient data from existing individual patient medical records into an electronic case report form (eCRF). The end of study was defined as the date of last data query resolution (i.e., all data had been recorded in the eCRF and all data queries resolved to allow database lock to occur). This ensured that all data was available to answer the research questions in the study.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2024-07-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06897657
The ClinicalTrials.gov registry entry for NCT06897657 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (72% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 0 interventions.
NCT06897657 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06897657 about?
NCT06897657 is a clinical study titled "A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients". This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data. UK MS centers with National Health Service (NHS) databases and/or homecare and pharmacy services prescribing ofatumumab...
What is the current status of trial NCT06897657?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2023-11-06. Estimated completion is 2024-07-25.
What conditions does trial NCT06897657 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
Who is sponsoring clinical trial NCT06897657?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06897657 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.